Esophageal Achalasia Market is projected to reach USD 598 million by 2034

The global Esophageal Achalasia Market was valued at USD 345 million in 2024 and is projected to reach USD 598 million by 2034, growing at a CAGR of 5.6% from 2025 to 2034. Growth is driven by rising prevalence of esophageal motility disorders, increased adoption of minimally invasive endoscopic procedures, improvements in diagnostic modalities such as high-resolution manometry (HRM), and growing clinical preference for pneumatic dilation and peroral endoscopic myotomy (POEM).

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71137

Esophageal achalasia is a rare neurodegenerative motility disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and loss of peristalsis in the esophageal body. Without treatment, patients experience progressive dysphagia, regurgitation, chest pain, and weight loss, significantly impacting quality of life. Modern interventional techniques have improved long-term outcomes, reducing reliance on traditional surgical approaches.

Key Market Highlights
• 2024 Market Size: USD 345 million
• 2034 Forecast: USD 598 million
• CAGR (2025-2034): 5.6%
• Largest Segment: Endoscopic therapies (POEM & pneumatic dilation)
• Fastest-Growing Segment: POEM and advanced robotic-assisted myotomy

Epidemiology & Clinical Insights
1. Prevalence
• Achalasia affects 1-3 per 100,000 individuals annually.
• Incidence rising due to improved diagnostic awareness.
• Most commonly diagnosed between ages 25-60 years, with no strong gender predominance.
2. Disease Subtypes (Chicago Classification)
• Type I (Classic achalasia): Minimal pressurization
• Type II: Pan-esophageal pressurization (best treatment response)
• Type III: Spastic achalasia (benefits most from POEM)
3. Key Symptoms
• Progressive dysphagia
• Regurgitation of undigested food
• Chest pain
• Aspiration risk
• Weight loss
4. Diagnostic Tools
• High-resolution manometry (HRM) - gold standard
• Barium esophagram
• Endoscopy
• Functional luminal imaging probe (FLIP)

Market Growth Drivers
1. Rapid Adoption of POEM (Peroral Endoscopic Myotomy)
Minimally invasive, highly effective, with strong outcomes for all achalasia subtypes, especially Type III.
2. Advancements in Interventional Endoscopy
Enhanced therapeutic endoscopy systems and improved visualization tools.
3. Growing Access to Specialized GI Motility Centers
Expansion of trained endoscopists globally, improving treatment availability.
4. Rising Awareness of Esophageal Motility Disorders
Increased clinical focus on dysphagia evaluation.
5. Improvements in Diagnostic Imaging
AI-assisted HRM interpretation and 3D esophageal pressure mapping increase accuracy.

Market Restraints
• Limited expertise for POEM in low-resource regions
• High procedure cost (particularly in private healthcare settings)
• Long-term reflux risk after myotomy
• Lack of pharmacologic cure; treatment remains procedural

Market Opportunities
1. Robotic-Assisted Myotomy
Greater precision and reduced complication rates.
2. AI-Based Motility Interpretation
Supports faster diagnosis and subtype classification.
3. New Pharmacologic Agents Under Investigation
LES relaxants and neuromodulators.
4. Expansion of FLIP Technology
Real-time evaluation of esophagogastric junction distensibility.
5. Global Training Programs for POEM
Increasing patient access worldwide.

Segmentation Overview
By Treatment
• Pharmacologic therapy (nitrates, calcium channel blockers; limited role)
• Botulinum toxin injection
• Pneumatic balloon dilation
• Peroral endoscopic myotomy (POEM)
• Laparoscopic Heller myotomy (LHM)
• Endoscopic fundoplication (for reflux management)

By Disease Type
• Type I achalasia
• Type II achalasia
• Type III achalasia

By End User
• Hospitals
• Ambulatory surgical centers
• Specialty gastroenterology clinics

Explore Full Report here: https://exactitudeconsultancy.com/reports/71137/esophageal-achalasia-market

Regional Insights
North America - Largest Market
Strong adoption of POEM, presence of expert GI motility centers, and rapid uptake of advanced manometry technologies.
Europe - Strong Diagnostic and Treatment Infrastructure
Germany, France, Italy, and the UK lead in advanced endoscopic procedures.
Asia Pacific - Fastest Growing
Centers in Japan, South Korea, China, and India rapidly increasing POEM adoption due to high procedural expertise.
Latin America - Developing
Growing access to pneumatic dilation and early introduction of POEM.
Middle East & Africa - Emerging
Gradual expansion of diagnostic modalities and specialized GI care.

Competitive Landscape
Key companies active in the esophageal achalasia space include:
• Medtronic
• Olympus Corporation
• Ethicon (Johnson & Johnson)
• Cook Medical
• Boston Scientific
• Pentax Medical
• Fujifilm Holdings
• STERIS
• Conmed Corporation
Product areas include endoscopic systems, manometry devices, dilation balloons, therapeutic knives, and imaging tools.

Recent Market Developments
• Growing global expansion of POEM training programs
• Introduction of next-generation high-definition endoscopes
• AI-based HRM analysis tools entering clinical practice
• Expanded use of FLIP for intraoperative guidance
• Improved endoscopic suturing devices for reflux prevention

Future Outlook (2025-2034)
The Esophageal Achalasia Market will continue to expand as:
• Minimally invasive procedures replace traditional surgery
• AI and advanced motility diagnostics improve detection and subtype classification
• POEM becomes standard of care globally
• Robotic and hybrid endoscopic platforms evolve
• Patient awareness and access to specialized centers increase
By 2034, the market is projected to reach USD 598 million, supported by innovation in GI motility diagnostics and therapeutic endoscopy.

This report is also available in the following languages : Japanese (食道アカラシア市場), Korean (식도 아칼라시아 시장), Chinese (食管贲门失弛症市场), French (Marché de l'achalasie œsophagienne), German (Markt für Ösophagusachalasia), and Italian (Mercato dell'acalasia esofagea), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71137

Our More Reports:

Gastrointestinal Drugs Market
https://exactitudeconsultancy.com/reports/60463/global-gastrointestinal-drugs-market

GI Stents Market
https://exactitudeconsultancy.com/reports/60920/global-gi-stents-market

Proton Pump Inhibitors Market
https://exactitudeconsultancy.com/reports/63889/global-proton-pump-inhibitors-market

Achalasia Treatment Market
https://exactitudeconsultancy.com/reports/66032/achalasia-treatment-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.